BiotechTube

ONTAK

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin's Lymphoma

Conditions

Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Lymphoma, Low-grade

Trial Timeline

May 1, 2000 → Sep 1, 2006

NCT ID
NCT00051025

About ONTAK

ONTAK is a phase 2 stage product being developed by Eisai for Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00051025. Target conditions include Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Lymphoma, Low-grade.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT00726037Phase 2Terminated
NCT00055146Phase 2Completed
NCT00051025Phase 2Completed
NCT00051012ApprovedCompleted
NCT00050999ApprovedCompleted

Competing Products

20 competing products in Non-Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
ABT-199 + KetoconazoleAbbViePhase 1
33
ABT-199 + RifampinAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + Rituximab + BendamustineAbbViePhase 1
33
ABBV-291AbbViePhase 1
33
ABT-199AbbViePhase 1
33
AvelumabMerckPhase 1
33
Pembrolizumab + Flt3L + Poly ICLCMerckPhase 1/2
41

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85